Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Mildvan

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
American Journal of Public Health|June 30, 2005
HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention servicesDon C Des Jarlais, Theresa Perlis, Kamyar Arasteh, et al.
The Journal of Infectious Diseases|November 19, 2003
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimenAlan L Landay, John Spritzler, Harold Kessler, et al.
HIV Clinical Trials|February 13, 2014
Minorities remain underrepresented in HIV/AIDS research despite access to clinical trialsJose R Castillo-Mancilla, Susan E Cohn, Supriya Krishnan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
AIDS and Behavior|June 26, 2014
ACT2 peer-driven intervention increases enrollment into HIV/AIDS medical studies among African Americans/Blacks and Hispanics: A cluster randomized controlled trialMarya Gwadz, Charles M Cleland, Mindy Belkin, et al.
Journal of Clinical Immunology|April 12, 2005
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067Ronald D'Amico, Yijun Yang, Donna Mildvan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2002
Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantationLeonard H Calabrese, Michael M Lederman, John Spritzler, et al.
AIDS and Behavior|March 31, 2009
An exploratory behavioral intervention trial to improve rates of screening for AIDS clinical trials among racial/ethnic minority and female persons living with HIV/AIDSMarya Viorst Gwadz, Keith Cylar, Noelle R Leonard, et al.
Frontiers in Public Health|August 1, 2014
HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited CohortsMarya Gwadz, Elizabeth Applegate, Charles Cleland, et al.
The Journal of Infectious Diseases|May 4, 2004
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment responseDonna Mildvan, Ronald J Bosch, Ryung S Kim, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
American Journal of Public Health|June 30, 2005
HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention servicesDon C Des Jarlais, Theresa Perlis, Kamyar Arasteh, et al.
The Journal of Infectious Diseases|November 19, 2003
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimenAlan L Landay, John Spritzler, Harold Kessler, et al.
HIV Clinical Trials|February 13, 2014
Minorities remain underrepresented in HIV/AIDS research despite access to clinical trialsJose R Castillo-Mancilla, Susan E Cohn, Supriya Krishnan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.
AIDS and Behavior|June 26, 2014
ACT2 peer-driven intervention increases enrollment into HIV/AIDS medical studies among African Americans/Blacks and Hispanics: A cluster randomized controlled trialMarya Gwadz, Charles M Cleland, Mindy Belkin, et al.
Journal of Clinical Immunology|April 12, 2005
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067Ronald D'Amico, Yijun Yang, Donna Mildvan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 28, 2002
Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantationLeonard H Calabrese, Michael M Lederman, John Spritzler, et al.
AIDS and Behavior|March 31, 2009
An exploratory behavioral intervention trial to improve rates of screening for AIDS clinical trials among racial/ethnic minority and female persons living with HIV/AIDSMarya Viorst Gwadz, Keith Cylar, Noelle R Leonard, et al.
Frontiers in Public Health|August 1, 2014
HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited CohortsMarya Gwadz, Elizabeth Applegate, Charles Cleland, et al.
The Journal of Infectious Diseases|May 4, 2004
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment responseDonna Mildvan, Ronald J Bosch, Ryung S Kim, et al.
Pageof 5